Antares Pharma
Market Cap
US$346.0m
Last Updated
2020/04/02 02:22 UTC
Data Sources
Company Financials +
Executive Summary
Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide.
Rewards
Risk Analysis
Snowflake Analysis
Reasonable growth potential with mediocre balance sheet.
Similar Companies
Share Price & News
How has Antares Pharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ATRS's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-5.0%
ATRS
-1.7%
US Medical Equipment
-4.1%
US Market
1 Year Return
-26.9%
ATRS
-8.2%
US Medical Equipment
-14.9%
US Market
Return vs Industry: ATRS underperformed the US Medical Equipment industry which returned -7.8% over the past year.
Return vs Market: ATRS underperformed the US Market which returned -13.6% over the past year.
Shareholder returns
| ATRS | Industry | Market | |
|---|---|---|---|
| 7 Day | -5.0% | -1.7% | -4.1% |
| 30 Day | -32.8% | -14.1% | -19.1% |
| 90 Day | -50.9% | -19.2% | -23.4% |
| 1 Year | -26.9%-26.9% | -7.4%-8.2% | -13.2%-14.9% |
| 3 Year | -29.6%-29.6% | 40.6%36.8% | 10.7%3.5% |
| 5 Year | -26.4%-26.4% | 69.3%51.7% | 28.5%14.5% |
Price Volatility Vs. Market
How volatile is Antares Pharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Does Antares Pharma (NASDAQ:ATRS) Have A Healthy Balance Sheet?4 weeks ago | Simply Wall St
Antares Pharma, Inc. Just Released Its Full-Year Earnings: Here's What Analysts Think1 month ago | Simply Wall St
Antares Pharma (NASDAQ:ATRS) Shareholders Have Enjoyed A 53% Share Price GainValuation
Is Antares Pharma undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ATRS ($2.09) is trading below our estimate of fair value ($10.47)
Significantly Below Fair Value: ATRS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ATRS is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: ATRS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ATRS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ATRS is overvalued based on its PB Ratio (6.3x) compared to the US Medical Equipment industry average (2.9x).
Next Steps
Future Growth
How is Antares Pharma forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
40.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ATRS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: ATRS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ATRS's is expected to become profitable in the next 3 years.
Revenue vs Market: ATRS's revenue (16.7% per year) is forecast to grow faster than the US market (7.2% per year).
High Growth Revenue: ATRS's revenue (16.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ATRS's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Antares Pharma performed over the past 5 years?
31.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ATRS is currently unprofitable.
Growing Profit Margin: ATRS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ATRS is unprofitable, but has reduced losses over the past 5 years at a rate of 31.5% per year.
Accelerating Growth: Unable to compare ATRS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ATRS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1%).
Return on Equity
High ROE: ATRS has a negative Return on Equity (-3.72%), as it is currently unprofitable.
Next Steps
Financial Health
How is Antares Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: ATRS's short term assets ($108.4M) exceed its short term liabilities ($32.4M).
Long Term Liabilities: ATRS's short term assets ($108.4M) exceed its long term liabilities ($45.8M).
Debt to Equity History and Analysis
Debt Level: ATRS's debt to equity ratio (74.1%) is considered high.
Reducing Debt: Insufficient data to determine if ATRS's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Inventory Level: ATRS has a high level of physical assets or inventory.
Debt Coverage by Assets: ATRS's debt is covered by short term assets (assets are 2.7x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ATRS has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ATRS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Antares Pharma's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ATRS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ATRS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ATRS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ATRS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ATRS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.6yrs
Average management tenure
CEO
Bob Apple (53yo)
4.25s
Tenure
US$3,452,880
Compensation
Mr. Robert F. Apple, also known as Bob, has been the Chief Executive Officer and President of Antares Pharma Inc. since January 25, 2016. Mr. Apple served as Chief Operating Officer of Antares Pharma Inc. ...
CEO Compensation Analysis
Compensation vs Market: Bob's total compensation ($USD3.45M) is above average for companies of similar size in the US market ($USD2.20M).
Compensation vs Earnings: Bob's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 4.25yrs | US$3.45m | 1.22% $4.2m | |
| Executive VP & CFO | 3.5yrs | US$1.33m | 0.21% $710.0k | |
| Executive VP of Human Resources | 4.75yrs | US$1.35m | 0.14% $501.3k | |
| Executive VP | 1.67yrs | US$745.48k | no data | |
| Senior Vice President of Operations | no data | no data | no data | |
| Principal Accounting Officer | 3.58yrs | US$361.46k | no data | |
| Senior Vice President of Corporate Development | 0.33yr | no data | no data | |
| Senior Vice President of Technology Portfolio & Intellectual Property | no data | US$467.99k | no data | |
| Senior Vice President of Regulatory Affairs & Quality Assurance | 4.08yrs | no data | no data | |
| Senior Vice President of Commercial | no data | no data | no data |
3.6yrs
Average Tenure
55yo
Average Age
Experienced Management: ATRS's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 4.25yrs | US$3.45m | 1.22% $4.2m | |
| Independent Director | 6.75yrs | US$167.00k | 0.053% $184.3k | |
| Independent Chairman | 11.5yrs | US$327.50k | 0.11% $365.9k | |
| Independent Director | 6.92yrs | US$165.00k | 0.017% $58.1k | |
| Independent Director | 16.5yrs | US$182.82k | 0.10% $355.7k | |
| Independent Director | 16.5yrs | US$186.82k | 0.18% $632.8k | |
| Independent Director | 1.33yrs | US$35.32k | no data | |
| Independent Director | 1.08yrs | no data | no data |
6.8yrs
Average Tenure
62.5yo
Average Age
Experienced Board: ATRS's board of directors are considered experienced (6.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.3%.
Top Shareholders
Company Information
Antares Pharma, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Antares Pharma, Inc.
- Ticker: ATRS
- Exchange: NasdaqCM
- Founded: 1978
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$346.021m
- Shares outstanding: 165.56m
- Website: https://www.antarespharma.com
Number of Employees
Location
- Antares Pharma, Inc.
- 100 Princeton South
- Suite 300
- Ewing
- New Jersey
- 8628
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ATRS | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Feb 2001 |
| MJC | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Feb 2001 |
| MJC | BRSE (Berne Stock Exchange) | Yes | Common Stock | CH | CHF | Feb 2001 |
Biography
Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company’s injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Epinephrine Injection USP for treating Anaphylaxis; Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector EZ II Needle-free Injectors to administer human growth hormone for patients with growth retardation. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; and QuickShot auto injectors. It has strategic alliances with Teva Pharmaceutical Industries, Ltd., AMAG Pharmaceuticals, Inc., and Pfizer Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/04/02 02:22 |
| End of Day Share Price | 2020/04/01 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.